|Nabi Biopharmaceuticals to Present at Rodman & Renshaw's Annual Global Investment Conference|
ROCKVILLE, Md., Sep 7, 2010 (GlobeNewswire via COMTEX) --
Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that Dr. Raafat Fahim, President and Chief Executive Officer, will present at the Rodman & Renshaw Annual Global Investment Conference held on September 13-15, 2010 at the New York Palace Hotel in New York, NY. Dr. Fahim's presentation is scheduled for Tuesday, September 14, 2010 at 3:15 p.m. EDT.
You can access the web cast of this presentation on the company's "Events and Webcasts" page at www.nabi.com or at http://www.wsw.com/webcast/rrshq18/nabi.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(R) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit www.nabi.com.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Nabi Biopharmaceuticals
CONTACT: Nabi Biopharmaceuticals Investor Relations 301-770-3099 www.nabi.com